The American Journal of Medicine
Volume 122, Issue 4 , Pages 348-355 , April 2009

Comorbidities, Patient Knowledge, and Disease Management in a National Sample of Patients with COPD

  • R. Graham Barr, MD, DrPH

      Affiliations

    • Division of General Medicine, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY
    • Division of Pulmonary, Allergy and Critical Care, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY
    • Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY
    • Corresponding Author InformationRequests for reprints should be addressed to R. Graham Barr, MD, DrPH, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032
    • ,
  • Bartolome R. Celli, MD

      Affiliations

    • Pulmonary and Critical Care Division, Caritas-St Elizabeth's Medical Center, Tufts University, Boston, Mass
    • ,
  • David M. Mannino, MD

      Affiliations

    • Department of Preventive Medicine and Environmental Health, University of Kentucky College of Public Health, Lexington
    • ,
  • Thomas Petty, MD

      Affiliations

    • Departments of Medicine, University of Colorado and Rush-Presbyterian St Luke's, Chicago, Ill
    • ,
  • Stephen I. Rennard, MD

      Affiliations

    • Pulmonary and Critical Care Medicine Section, Department of Internal Medicine, University of Nebraska Medical Center, Omaha
    • ,
  • Frank C. Sciurba, MD

      Affiliations

    • Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pa
    • ,
  • James K. Stoller, MD, MS

      Affiliations

    • Department of Pulmonary, Allergy, and Critical Care Medicine, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Byron M. Thomashow, MD

      Affiliations

    • Division of Pulmonary, Allergy and Critical Care, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY
    • ,
  • Gerard M. Turino, MD

      Affiliations

    • James P. Mara Center, St-Luke's-Roosevelt Hospital, New York, NY

References 

  1. Petty TL. Definition, epidemiology, course, and prognosis of COPD. Clin Cornerstone. 2003;5:1–10
  2. National Heart Lung Blood Institute Factbook FY-2006. Bethesda, MD: National Institutes of Health/National Heart, Lung, and Blood Institute; 2007;
  3. Hoyert DL, Arias E, Smith BL. Death: Final Data for 1999 (National Vital Statistics Reports 2001). Hyattsville, MD: National Center for Health Statistics; 2001;US Dept of Health and Human Services publication (PHS) 2001-1120;2001
  4. Schiller JS, Adams PF, Nelson ZC. Summary health statistics for the U.S. population: National Health Interview Survey, 2003. Vital Health Stat 10. 2005;1–104
  5. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(5 Suppl):121S–126S
  6. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498–1504
  7. Mensah GA, Brown DW, Croft JB, Greenlund KJ. Major coronary risk factors and death from coronary heart disease: baseline and follow-up mortality data from the Second National Health and Nutrition Examination Survey (NHANES II). Am J Prev Med. 2005;29(5 Suppl 1):68–74
  8. Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow-up study. Thorax. 2003;58:388–393
  9. Wouters EF, Creutzberg EC, Schols AM. Systemic effects in COPD. Chest. 2002;121(5 Suppl):127S–130S
  10. Skeletal muscle dysfunction in chronic obstructive pulmonary disease (A statement of the American Thoracic Society and European Respiratory Society). Am J Respir Crit Care Med. 1999;159(4 Pt 2):S1–S40
  11. de Vries F, van Staa TP, Bracke MS, et al. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J. 2005;25:879–884
  12. Jorgensen NR, Schwarz P, Holme I, et al. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med. 2007;101:177–185
  13. Himelhoch S, Lehman A, Kreyenbuhl J, et al. Prevalence of chronic obstructive pulmonary disease among those with serious mental illness. Am J Psychiatry. 2004;161:2317–2319
  14. Norwood R, Norwood R. Prevalence and impact of depression in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med. 2006;12:113–117
  15. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? (The potential role of systemic inflammation in chronic obstructive pulmonary disease). Circulation. 2003;107:1514–1519
  16. Schunemann HJ, Dorn J, Grant BJ, et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118:656–664
  17. Friedman GD, Klatsky AL, Siegelaub AB. Lung function and outcome of myocardial infarction. N Engl J Med. 1976;295:1323
  18. Curkendall SM, Lanes S, de Luise C, et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol. 2006;21:803–813
  19. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada. Ann Epidemiol. 2006;16:63–70
  20. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005;128:2005–2011
  21. van Manen JG, Bindels PJ, IJzermans CJ, et al. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol. 2001;54:287–293
  22. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD. 2005;2:35–41
  23. Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128:2099–2107
  24. Sidney S, Sorel M, Quesenberry CP, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128:2068–2075
  25. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–586
  26. Barr RG, Celli BR, Martinez FJ, et al. Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med. 2005;118:1415
  27. Kahrilas PJ. Gastroesophageal reflux disease. JAMA. 1996;276:983–988
  28. Wijnhoven HA, Kriegsman DM, Hesselink AE, et al. The influence of co-morbidity on health-related quality of life in asthma and COPD patients. Respir Med. 2003;97:468–475
  29. Yeo J, Karimova G, Bansal S. Co-morbidity in older patients with COPD—its impact on health service utilisation and quality of life, a community study. Ageing. 2006;35:33–37
  30. Adams PF, Barnes PM. Summary health statistics for the U.S. population: National Health Interview Survey, 2004. Vital Health Stat 10. 2006;1–104
  31. The 2004 United States Surgeon General's Report: The Health Consequences of Smoking. N S W Public Health Bull. 2004;15:107
  32. Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347–360
  33. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28:1245–1257
  34. Walter RE, Wilk JB, Larson MG, et al. Systemic inflammation and COPD: The Framingham Heart Study. Chest. 2008;133:19–25Epub 2007 Oct 1
  35. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789
  36. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1 (The Lung Health Study). JAMA. 1994;272:1497–1505
  37. Barr RG, Bourbeau J, Camargo CA, Ram FSF. Inhaled tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2006;61:854–862
  38. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Repir J. 2008;31:204–212
  39. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166:333–339
  40. Kinnunen T, Saynajakangas O, Tuuponen T, Keistinen T. Impact of comorbidities on the duration of COPD patients' hospital episodes. Respir Med. 2003;97:143–146
  41. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128:2640–2646
  42. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? (A multiple cause coding analysis). Eur Respir J. 2003;22:809–814
  43. Mannino DM, Brown C, Giovino GA. Obstructive lung disease deaths in the United States from 1979 through 1993 (An analysis using multiple-cause mortality data). Am J Respir Crit Care Med. 1997;156(3 Pt 1):814–818
  44. Camilli AE, Robbins DR, Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol. 1991;133:795–800
  45. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279:585–592
  46. Learn More, Breathe Better Campaign. http://www.nhlbi.nih.gov/health/public/lung/copd/index.htmAccessed February 3, 2008
  47. Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest. 2001;119:1691–1695

 Funding: The COPD Foundation and National Institutes of Health HL077612 and HL075476.

 Conflict of Interest: R. Graham Barr, MD, DrPH: none. Bartolome R. Celli, MD: research grants from Glaxo Smith Kline (GSK), Boehringer Ingelheim (BI), Forrest Medical, Astra Zeneca; advisory board payments from GSK, BI, Almirall, Astra Zeneca; speakers' fees from GSK, BI, Astra Zeneca, Almirall. David Mannino, MD: research funding from GSK, Pfizer, and Novartis; consultant or speakers' fees from GSK, Pfizer, BI, Astra-Zeneca, Dey, and Sepracor. Thomas Petty, MD: none. Stephen I. Rennard, MD: research grants from Almirall, Lorillard, Centocor, Novartis, GSK, Philip Morris, Institute for Science and Health, Roche; consultancy and advisory board payments from Abbott, Johnson & Johnson, Almirall, Novartis, Altana, Roche, Anthera, Quintiles, GSK, Targegen; speakers' fees from Adams, Novartis, AstraZeneca, Pfizer. Frank C. Sciurba, MD: consultancy for Astra Zeneca, BI, Dey, GSK, Novartis, Pfizer, PneumRX, Respironics, Schering and Sepracor. James K. Stoller, MD, MS: consultancy for Talecris Biotherapeutics, BI; speaker for Grifols, Baxter, CSL-Behring, Pfizer, Talecris. Byron M. Thomashow, MD: speakers' fees and consultancy for BI, Pfizer and GSK. Gerard M. Turino, MD: research grant from BI; consultancy for Talecris Corporation.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(08)01072-3

doi: 10.1016/j.amjmed.2008.09.042

The American Journal of Medicine
Volume 122, Issue 4 , Pages 348-355 , April 2009

Article Tools

* Image Usage & Resolution